Insilico Medicine’s AI-driven approach yields promising PTPN2/N1 inhibitor for cancer immunotherapy Post author: Post published: April 14, 2024 Post category:uncategorized In recent years, cancer immunotherapy, exemplified by PD-1 and its ligand PD-L1 blockade, has made remarkable advances. You Might Also Like New AI model offers hope for detecting brain cancer spread without surgery Researchers Have Developed A… January 15, 2025 Non-COVID-19 mortality among people with diabetes increased during the pandemic January 23, 2024 New calculator accurately estimates the risk of dementia after a stroke January 29, 2026
New AI model offers hope for detecting brain cancer spread without surgery Researchers Have Developed A… January 15, 2025